Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TomoTherapy cuts jobs

This article was originally published in Clinica

Executive Summary

TomoTherapy last week joined the ever-growing list of companies undertaking cost-cutting measures with the announcement it was reducing its workforce by 12%. The Madison, Wisconsin firm said it will do so by laying off existing staff as well as eliminating open job positions. TomoTherapy CEO Fred Robertson deemed the action as "difficult, but necessary" in light of the company's decelerating growth in the current difficult economic conditions. With its revenues dependent on the sales of expensive capital equipment like its Hi-Art radiation therapy system, the firm has been hit particularly hard by the global financial turmoil. The company posted disappointing third-quarter results in October and its shareholders are pushing it to liquidate its assets (see Clinica Nos 1327, p 22 & 1328, p 20).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel